International EyeCare Laser Center Acquires Third ALLEGRETTO WAVE System from WaveLight.

Next Generation EYE-Q System Delivers Fastest LASIK Treatments in the Country

HOUSTON -- International EyeCare Laser Center announced today that it has installed its third ALLEGRETTO WAVE system at its Houston location. The ALLEGRETTO WAVE([R]) Eye-Q, sold by WaveLight, Inc. (FWB:WLT), is the newest FDA-approved LASIK system in the United States. It delivers the fastest and most precise laser vision correction treatments available, featuring advanced Wavefront Optimized[TM] technology.

"As one of the earliest ALLEGRETTO WAVE centers in the country, we have watched this platform deliver the most predictable, high-quality LASIK treatments for thousands of patients throughout the past seven years," said Charles Moore, M.D., FACS, Founder and Medical Director at International EyeCare Laser Center. "Now with the next generation Eye-Q laser, we can treat patients in half the time and more comfortably while maintaining the accuracy and safety that our patients have come to expect from International EyeCare Laser Center."

The Eye-Q system, manufactured by WaveLight AG, corrects one diopter of nearsightedness or farsightedness in just two seconds. Therefore, the average treatment time to complete the LASIK procedure is typically between just eight and ten seconds. Half the treatment time means decreased anxiety for the patient and less recovery time.

This next generation system features WaveLight's proprietary PerfectPulse Technology(TM) to ensure maximum safety at high speeds. PerfectPulse Technology was specifically developed to monitor and control each laser pulse that is delivered to the eye during the LASIK procedure. Another component of this technology is a high speed, active eye-tracking device which monitors eye movement 400 times per second and adjusts the laser beam accordingly in less than six milliseconds.

The Eye-Q also features WaveLight's proprietary Wavefront Optimized[TM] technology, which has been shown to preserve the natural shape of the eye and prevent the induction of optical errors that could lead to night vision problems or loss of contrast sensitivity (the ability to see the images crisply).

"Dr. Charles Moore is one of the most experienced ALLEGRETTO WAVE surgeons in the country and is duly recognized as a key educator and expert in photo-refractive surgery," said Wolfgang Tolle, CEO of WaveLight, Inc. "As the first US recipient of WaveLight's Global Ambassador award for his instrumental role in our FDA clinical trials, we are privileged to bring the Eye-Q to his successful practice."

About International EyeCare Laser Center

International EyeCare Laser Center is the only private practice in Houston exclusively dedicated to laser vision correction. Dr. Charles Moore has performed more than 40,000 Lasik procedures for Lasik patients from every state in America and from many countries around the world. The mission of International EyeCare is to make each LASIK patient's experience a pleasant and successful one.

WaveLight AG (ISIN DE 000 512 5603)

WaveLight AG has been listed on Deutsch Borse AG's Prime Standard segment since January 2003: The company, which develops, manufactures and markets a full range of high-quality products for ophthalmology, specializes in vision optics. The market success of WaveLight is based on a dense sales network comprised of WaveLight's own sales channels as well as the sales channels of strategic partners.

Further information on WaveLight is available at: www.wavelight.com/eyes

All information is given and all assessments are made on the basis of extremely conscientious research. However, no guarantee is given with regard to the information or assessments published. No liability whatsoever is accepted. The above statements do not represent an invitation to buy or sell securities. All rights reserved.

Disclaimer for Myopia:

a. Approval of the premarket approval application is for the WaveLight ALLEGRETTO WAVE[R] Eye-Q Excimer Laser System to perform LASIK treatments in patients 18 years of age or older for the reduction or elimination of myopic refractive errors up to -12.0 diopters (D) of sphere with and without astigmatic refractive errors up to -6.0 D; and in patients with documented evidence of a stable manifest refraction defined as en 0.50 D of preoperative spherical equivalent shift over one year prior to surgery.

b. LASIK is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), and other refractive surgeries.

c. Approval of the application is based on clinical trials in the United States with 901 eyes treated, of which 813 of 866 eligible eyes were followed for 12 months. Accountability at 3 months was 93.8%, at 6 months was 91.9%, and at 12 months was 93.9%.

d. The studies found that of the 844 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at the 3-month stability time point, 98.0% were corrected to 20/40 or better, and 84.4% were corrected to 20/20 or better without spectacles or contact lenses.

e. The clinical trials showed that the following subjective patient adverse events were reported as "moderate to severe" at a level at least 1% higher than baseline of the subjects at 3 months post-treatment: visual fluctuations (12.8% at baseline versus 28.6% at 3 months).

f. Long term risks of LASIK for myopia with and without astigmatism beyond 12 months have not been studied.

g. Note that the complete name for this ophthalmic laser is "WaveLight ALLEGRETTO WAVE[R] Eye-Q Excimer Laser System for laser assisted in situ keratomileusis (LASIK) treatments of myopic refractive errors up to -12.0 diopters (D) of sphere with and without astigmatic refractive errors up to -6.0 D at the spectacle plane".

Disclaimer for Hyperopia:

a. Approval of the premarket approval application is for the WaveLight ALLEGRETTO WAVE[R] Eye-Q Excimer Laser System to perform LASIK treatments in patients 18 years of age or older for the reduction or elimination of hyperopic refractive errors up to +6.0 diopters (D) of sphere with and without astigmatic refractive errors up to 5.0 D at the spectacle plane, with a maximum manifest refraction spherical equivalent (MRSE) of +6.0 D; and in patients with documented evidence of a stable manifest refraction defined as en 0.50 D of preoperative spherical equivalent shift over one year prior to surgery, exclusive of changes due to unmasking latent hyperopia.

b. LASIK is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), and other refractive surgeries.

c. Approval of the application is based on clinical trials in the United States with 290 eyes treated, of which 100 of 290 eligible eyes were followed for 12 months. Accountability at 3 months was 95.2%, at 6 months was 93.9%, and at 12 months was 69.9%.

d. The studies found that of the 212 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at the 6-month stability time point, 95.3% were corrected to 20/40 or better, and 67.5% were corrected to 20/20 or better without spectacles or contact lenses.

e. The study showed that the following subjective patient adverse events were reported as "much worse" by at least 1% of the subjects (in order of increasing frequency) at 6 months post final treatment: glare from bright lights (3%); night driving glare (4.2%); light sensitivity (4.9%); visual fluctuations (6.1%); and halos (6.4%).

f. Long term risks of LASIK for hyperopia with and without astigmatism beyond 12 months have not been studied.

g. Note that the complete name for this ophthalmic laser is "WaveLight ALLEGRETTO WAVE[R] Eye-Q Excimer Laser System for laser assisted in situ keratomileusis (LASIK) treatments of hyperopic refractive errors up to +6.0 diopters (D) of with and without astigmatic refractive errors up to 5.0 D with a maximum manifest refraction spherical equivalent (MRSE) of +6.0 D".